Bone drugs' safety doubted

Share this article:
A new U.S. Food and Drug Administration analysis raises questions about long-term effectiveness among women of the widely prescribed osteoporosis drugs known as bisphosphonates.

The safety of the bone-building drugs, which include brands such as Boniva and Reclast, has been a topic of debate. The FDA's analysis found that after three to five years of use, bisphosphonates offer little to no benefit.

FDA reviewers said it's possible long-term use of the drugs could actually weaken bones, leading to adverse events such as femur fractures and esophageal cancer.
Share this article:
close

Next Article in News

More in News

CMS expands therapy payment research

The government is expanding its research into alternative therapy payments, to consider more holistic changes to the way Medicare reimburses skilled nursing facilities, the Centers for Medicare & Medicaid Services announced Tuesday.

CDC tightens Ebola guidelines for healthcare workers

The Centers for Disease Control and Prevention has issued more stringent guidelines for how healthcare workers should interact with Ebola patients, following an outcry from nurses and other professionals.

Nonprofit providers face alarming market forces, must rally, LeadingAge chairman says

Nonprofit providers face alarming market forces, must rally, ...

Nonprofit long-term care providers must work together to address alarming trends, or their market share could plummet and the sector as a whole could falter, LeadingAge Chairman David Gehm told ...